Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives
Background: Colorectal cancer is one of the most frequent and deadly malignancies worldwide. This specific pathology is composed of various molecular entities, with distinct immunological phenotypes. In addition to KRAS, NRAS and BRAF mutation status, other druggable alterations such as those in HER2, MET, NTRK, ALK, and ROS1 have been identified in recent years offering new therapeutic options for some patients with colorectal cancer.
Aim: This review will focus on the molecular biology, immunological fingerprints, and current clinical evidence for the use of immunotherapy in patients with colorectal cancer. Relevance for patients: High microsatellite instability (MSI-H) and mutations in mismatch repair genes constitute a new molecular entity within colorectal cancer, which is characterized by a high mutational and neoantigen burden, frequent immune cell infiltration, and where immune checkpoint inhibitors have shown high response and survival rates compared to microsatellite stable (MSS) tumors. Indeed, the approval of pembrolizumab in MSI-H tumors was the first agnostic FDA approval in solid tumors. While monotherapy with anti-PD-1 agents achieves objective response rates (ORR) of around 30% and 1-year overall survival (OS) rates of 76%, anti-PD1 and anti-CTLA4 combinations achieve a 55% ORR and a 1-year OS rate of 85%. Several ongoing trials are evaluating the use of different immunotherapy combinations, both in the advanced and early settings and in MSI-h and MSS colorectal cancers.
[1] Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods. Int J Cancer 2019;144:1941-53.
[2] Lui RN, Tsoi KK, Ho JM, Lo CM, Chan FC, Kyaw MH, et al. Global Increasing Incidence of YoungOnset Colorectal Cancer Across 5 Continents: A Joinpoint Regression Analysis of 1, 922, 167 Cases. Cancer Epidemiol Biomarkers Prev 2019;28:1275-82.
[3] Aleksandrova K, Pischon T, Jenab M, Bueno-de-MesquitaHB, Fedirko V, Norat T, et al. Combined Impact Of Healthy Lifestyle Factors on Colorectal Cancer: A Large European Cohort Study. BMC Med 2014;12:168.
[4] Kohler LN, Garcia DO, Harris RB, Oren E, Roe DJ, Jacobs ET. Adherence to Diet and Physical Activity Cancer Prevention Guidelines and Cancer Outcomes: A Systematic Review. Cancer Epidemiol Biomarkers Prev 2016;25:1018-28.
[5] Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal Cancer. Nat Rev Dis Primers 2015;1:15065.
[6] Dienstmann R, Salazar R, Tabernero J. Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. Am Soc Clin Oncol Educ Book 2018;38:231-8.
[7] Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with MismatchRepair Deficiency. N Engl J Med 2015;372:2509-20.
[8] Sillo TO, Beggs AD, Morton DG, Middleton G. Mechanisms of Immunogenicity in Colorectal Cancer. Br J Surg 2019;106:1283-97.
[9] Golshani G, Zhang Y. Advances in Immunotherapy for Colorectal Cancer: A Review. Therap Adv Gastroenterol 2020;13:1756284820917527.
[10] Cohen R, Shi Q, André T. Immunotherapy for Early-Stage Colorectal Cancer: A Glance into the Future. Cancers (Basel) 2020;12:1990.
[11] Garrido-Ramos MA. Satellite DNA: An Evolving Topic. Genes (Basel) 2017;8:230.
[12] Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, et al. Microsatellite Instability in Patients with Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol 2021;39:642-51.
[13] Kim JE, Hong YS, Kim HJ, Kim KP, Kim SY, Lim SB, et al. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX). Ann Surg Oncol 2017;24:1289-94.
[14] Koenig JL, Toesca DA, Harris JP, Tsai CJ, Haraldsdottir S, Lin AY, et al. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer. Am J Clin Oncol 2019;42:573-80.
[15] Petrelli F, Ghidini M, Cabiddu M, Pezzica E, Corti D, Turati L, et al. Microsatellite Instability and Survival in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis. Anticancer Res 2019;39:6431-41.
[16] Lower SS, McGurk MP, Clark AG, Barbash DA. Satellite DNA Evolution: Old Ideas, New Approaches. Curr Opin Genet Dev 2018;49:70-8.
[17] Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, et al. Inactivation of DNA Repair Triggers Neoantigen Generation and Impairs Tumour Growth. Nature 2017;552:116-20.
[18] Martini G, Dienstmann R, Ros J, Baraibar I, CuadraUrteaga JL, Salva F, et al. Molecular Subtypes and the Evolution of Treatment Management in Metastatic Colorectal Cancer. Ther Adv Med Oncol 2020;12:1758835920936089.
[19] Ünlü M, Uzun E, Bengi G, Sağol Ö, Sarıoğlu S. Molecular Characteristics of Colorectal Hyperplastic Polyp Subgroups. Turk J Gastroenterol 2020;31:573-80.
[20] Müller MF, Ibrahim AE, Arends MJ. Molecular Pathological Classification of Colorectal Cancer. Virchows Arch 2016;469:125-34.
[21] Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, et al. Impact of Consensus Molecular Subtype on Survival in Patients with Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). J Clin Oncol 2019;37:1876-85.
[22] Zhang Y, Zhang Z. The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and their Therapeutic Implications. Cell Mol Immunol 2020;17:807-21.
[23] Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, et al. Mechanisms of Resistance to Anti-EGFR Therapy in Colorectal Cancer. Oncotarget 2017;8:3980-4000.
[24] Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 2020;383:1207-17.
[25] Jiao D, Yang S. Overcoming Resistance to Drugs Targeting KRASG12C Mutation. Innovation (NY) 2020;1:100035.
[26] Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy According to Biomarker Status of Cetuximab plus FOLFOX-4 as First-Line Treatment for Metastatic Colorectal Cancer: The OPUS Study. Ann Oncol 2011;22:1535-46.
[27] Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab as FirstLine Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial. Lancet Oncol 2014;15:1065-75.
[28] Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, et al. First-Line Chemotherapy for mCRC-a Review and Evidence-Based Algorithm. Nat Rev Clin Oncol 2015;12:607-19.
[29] Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive Value of Primary Tumour Side in Patients with RAS wild-Type Metastatic Colorectal Cancer Treated with Chemotherapy and EGFR Directed Antibodies in Six Randomized Trials. Ann Oncol 2017;28:1713-29.
[30] Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The Relevance of Primary Tumour Location in Patients with Metastatic Colorectal Cancer: A Meta-Analysis of First-Line Clinical Trials. Eur J Cancer 2017;70:87-98. [31] Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et al. Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. J Natl Cancer Inst 2015;107:dju427.
[32] Abrahao ABK, Karim S, Colwell B, Berry S, Biagi J. The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement. Curr Oncol 2017;24:390-400.
[33] Tejpar S, Stintzing S, Ciardiello F, Tabernero J, van Cutsem E, Beier F, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol 2017;3:194-201.
[34] Cao DD, Xu HL, Xu XM, Ge W. The Impact of Primary Tumor Location on Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients with Different Kras Status: A Systematic Review and Meta-Analysis. Oncotarget 2017;8:53631-41.
[35] Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, et al. Primary Tumor Sidedness and Benefit from FOLFOXIRI Plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer. Retrospective Analysis of the TRIBE Trial by GONO. Ann Oncol 2018;29:1528-34.
[36] O’Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. Safety and Antitumor Activity of the Anti-PD-1 Antibody Pembrolizumab in Patients with Advanced Colorectal Carcinoma. PLoS One 2017;12:e0189848.
[37] Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade. Science 2017;357:409-13.
[38] Le DT, Kim TW, van Cutsem E, Geva R, Jäger D, Hara H, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/ Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol 2020;38:11-9.
[39] Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study. Lancet Oncol 2017;18:1182-91.
[40] Overman MJ, Lonardi S, Wong KY, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/ Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 2018;36:773-9.
[41] André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in Microsatellite-InstabilityHigh Advanced Colorectal Cancer. N Engl J Med 2020;383:2207-18.
[42] Battaglin F, Naseem M, Lenz HJ, Salem ME. Microsatellite Instability in Colorectal Cancer: Overview of its Clinical Significance and Novel Perspectives. Clin Adv Hematol Oncol 2018;16:735-45.
[43] de Smedt L, Lemahieu J, Palmans S, Govaere O, Tousseyn T, van Cutsem E, et al. Microsatellite Instable vs Stable Colon Carcinomas: Analysis of Tumour Heterogeneity, Inflammation and Angiogenesis. Br J Cancer 2015;113:500-9.
[44] Bonneville R, Krook MA, Chen HZ, Smith A, Samorodnitsky E, Wing MR, et al. Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing. Methods Mol Biol 2020;2055:119-32.
[45] Jabbar KJ, Luthra R, Patel KP, Singh RR, Goswami R, Aldape KD, et al. Comparison of Next-Generation Sequencing Mutation Profiling with BRAF and IDH1 Mutation-Specific Immunohistochemistry. Am J Surg Pathol 2015;39:454-61.
[46] Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and AntiCTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front Oncol 2018;8:86.
[47] Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, di Bartolomeo M, et al. Atezolizumab With or Without Cobimetinib Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer (IMblaze370): AMulticentre, Open-Label, Phase 3, Randomised, Controlled Trial. Lancet Oncol 2019;20:849-61.
[48] Mettu NB, Twohy E, Ou F, Halfdanarson TR, Lenz HJ, R. Breakstone et al. BACCI: A Phase II Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Capecitabine (C), Bevacizumab (B) Plus Atezolizumab (A) or Placebo (P) in Refractory Metastatic Colorectal Cancer (mCRC): An ACCRU Network Study. Ann Oncol 2019;30 Suppl 5:v198-252.
[49] Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The Immunoscore: Colon Cancer and Beyond. Clin Cancer Res 2020;26:332-9.
[50] Koulouridi A, Messaritakis I, Gouvas N, Tsiaoussis J, Souglakos J. Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation-A Special Reference to Colorectal Cancer. Cancers (Basel) 2020;13:43.
[51] Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GA, Gasbarrini A, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms 2019;7:14.
[52] Fong W, Li Q, Yu J. Gut Microbiota Modulation: A Novel Strategy for Prevention and Treatment of Colorectal Cancer. Oncogene 2020;39:4925-43.
[53] Liu D, Jenkins RW, Sullivan RJ. Mechanisms of Resistance to Immune Checkpoint Blockade. Am J Clin Dermatol 2019;20:41-54.
[54] Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov 2017;7:188-201.
[55] Kim R, Imanirad I, Carballido E, Strosberg J, Kim Y, Kim D. Phase I/IB Study of Regorafenib and Nivolumab in Mismatch Repair Proficient Advanced Refractory Colorectal Cancer. Moffitt Cancer Center, Tampa, United States. Ann Oncol 2020;31:S239.
[56] Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, et al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol 2020;38:2053-61.
[57] Bendell J, Ciardiello F, Tabernero J, Tebbutt N, Eng C, di Bartolomeo M, et al. Efficacy and Safety Results from IMblaze370, a Randomised Phase III Study Comparing Atezolizumab+cobimetinib and Atezolizumab Monotherapy vs Regorafenib in ChemotherapyRefractory Metastatic Colorectal Cancer. Ann Oncol 2018;29:v123.
[58] Loree JM, Jonker DJ, Feilotter H, Kennecke HF, Brohawn PZ, Banks K, et al. Impact of Clonality and DNA Repair Mutations on Plasma Tumour Mutation Burden (pTMB) and Immunotherapy Efficacy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) in CCTG CO.26. Ann Oncol 2020;30:1-2.
[59] Balibegloo M, Rezaei N. Development and Clinical Application of Bispecific Antibody in the Treatment of Colorectal Cancer. Expert Rev Clin Immunol 2020;16:689- 709.
[60] Tabernero J, Melero I, Ros W, Argiles G, Marabelle A, Rodriguez-Ruiz ME, et al. Phase Ia and Ib Studies of the Novel Carcinoembryonic Antigen (CEA) T-Cell Bispecific (CEA CD3 TCB) Antibody as a Single Agent and in Combination With Atezolizumab: Preliminary Efficacy and Safety in Patients with Metastatic Colorectal Cancer (mCRC). J Clin Oncol 2017;35:3002.
[61] Hecht JR, Chan A, Martin M, Mach N, Hurvitz SA, Rottey S, et al. Phase Ib Study of Talimogene Laherparepvec (T-VEC) Injection Into Liver Metastases (LMs) in Combination with Intravenous (IV) Atezolizumab in Patients (pts) with Metastatic Triple-Negative Breast Cancer (TNBC) or Colorectal Cancer (CRC). J Clin Oncol 2019;37:2.
[62] Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med 2016;375:2255-62.
[63] van Cutsem E, Machiels J, van den Eynde M, Prenen H, Hendlisz A, Shaza L, et al. Phase 1 Studies Assessing the Safety and Clinical Activity of Autologous and Allogeneic NKG2D-Based CAR-T Therapy in Metastatic Colorectal Cancer. Ann Oncol 2019;30:1-2.
[64] Murad JM, Graber DJ, Sentman CL. Advances in the Use of Natural Receptor-or Ligand-Based Chimeric Antigen Receptors (CARs) in Haematologic Malignancies. Best Pract Res Clin Haematol 2018;31:176-83.
[65] Chalabi M, Fanchi LF, Dijkstra KK, van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant Immunotherapy Leads to Pathological Responses in MMR-Proficient and MMR-Deficient Early-Stage Colon Cancers. Nat Med 2020;26:566-76.